Funded Biotechnology Startups in Newcastle Upon Tyne
Newcastle Upon Tyne has maintained a consistent pipeline of early-stage biotechnology funding across 2021–2025.
Newcastle Upon Tyne has maintained a consistent pipeline of early-stage biotechnology funding across 2021–2025. Of the ten most recent rounds on record, five are Seed raises — including InvenireX ($3M, November 2025), ScubaTx ($2M, September 2024), and PulmoBiomed ($880K, February 2024) — reflecting a cluster of pre-Series A companies at varying stages of maturity. Three further rounds carry a Series Unknown classification, covering Newcells Biotech ($2M, December 2024), NunaBio ($1M, September 2024), and Hexis Lab ($610K, May 2023).
The largest disclosed rounds in this set date to 2021: Iksuda Therapeutics at $48M and QuantuMDx Group at $20M. Since then, deal sizes have trended markedly smaller, with every 2023–2025 round falling between $570K (GlycanAge) and $3M (InvenireX). That pattern points to an ecosystem oriented around early-stage capital formation rather than late-stage consolidation.
Most recent rounds
10 shownRelated listings
Frequently asked
What are the largest rounds among Newcastle biotech companies in this dataset?
Iksuda Therapeutics leads with a $48M round closed in June 2021, followed by QuantuMDx Group's $20M venture round in November 2021. No round since then has exceeded $3M in the ten entries shown, with InvenireX's November 2025 Seed being the current high-water mark for recent activity.
What round stages are most common for Newcastle biotech startups?
Seed is the most frequent stage, accounting for five of the ten rounds shown — InvenireX, GlycanAge, ScubaTx, PulmoBiomed, and MarraBio. Three rounds carry a Series Unknown or Venture - Series Unknown classification (Newcells Biotech, NunaBio, Hexis Lab, QuantuMDx Group), and Iksuda Therapeutics has no stage disclosed.
How active has Newcastle biotech funding been in 2024 and 2025?
Six of the ten rounds on record closed between January 2024 and November 2025: InvenireX ($3M, Nov 2025), GlycanAge ($570K, May 2025), Newcells Biotech ($2M, Dec 2024), NunaBio ($1M, Sep 2024), ScubaTx ($2M, Sep 2024), and PulmoBiomed ($880K, Feb 2024), indicating consistent deal flow through the period.
What is the typical deal size for Seed rounds in Newcastle biotech?
The five Seed rounds in this dataset range from $570K (GlycanAge, May 2025) to $3M (InvenireX, November 2025), with MarraBio ($620K), PulmoBiomed ($880K), and ScubaTx ($2M) filling the middle. The median falls around $880K, reflecting an early-stage, capital-light profile.
Which Newcastle biotech companies raised most recently?
InvenireX is the most recent, closing a $3M Seed in November 2025. GlycanAge ($570K Seed, May 2025) and Newcells Biotech ($2M Series Unknown, December 2024) are the next two most recent closings in the dataset.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.